Related Experiment Video
Updated: Jun 20, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Coronary bypass surgery in patients treated with clopidogrel. Is it safe?
Thierry Carrel1, Lars Englberger
1Department of Cardiovascular Surgery, University Hospital Berne (Inselspital), Berne, Switzerland. thierry.carrel@insel.ch
Insights
Prior clopidogrel use moderately increases bleeding risk after coronary artery bypass grafting (CABG). Balancing this risk against potential coronary events is crucial for individual patient management.
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Pharmacology
Background:
- Current guidelines recommend initiating clopidogrel before coronary angiography for acute coronary syndrome.
- Early or continued clopidogrel exposure before coronary artery bypass grafting (CABG) may increase bleeding complications.
Purpose of the Study:
- To evaluate the bleeding risk associated with clopidogrel use prior to CABG.
- To assess the clinical implications of guideline adherence regarding clopidogrel discontinuation before CABG.
Main Methods:
- Review of existing literature on clopidogrel exposure and bleeding complications in CABG patients.
- Analysis of data from recent trials controlling for confounding factors.
Main Results:
- Earlier studies may have overestimated bleeding risk (5-10 fold increase) with prior clopidogrel exposure.
- A 2-3 fold increase in reexploration for bleeding is observed in properly matched trials.
- Guideline recommendations for clopidogrel discontinuation (5-7 days) before urgent CABG are not consistently followed.
Conclusions:
- Prior clopidogrel exposure presents a moderate bleeding risk after CABG.
- This risk is often compounded in patients with pre-existing surgical risk factors.
- Stopping clopidogrel before CABG increases hospitalization and carries a 1% risk of coronary events; risk-benefit must be individualized.
Purpose Of Review:
Current guidelines for the management of acute coronary syndrome clearly recommend that clopidogrel should be started before diagnostic coronary angiography. If patients undergo coronary artery bypass grafting (CABG) early after clopidogrel loading or during continued exposure, it seems reasonable to expect an increase in bleeding complications.
Recent Findings:
Earlier studies may have overestimated the risk of bleeding in patient undergoing CABG with prior clopidogrel exposure (5-10-fold increase). Some conflicting results are reported in literature. As reexploration because of excessive bleeding is concerned, a two to three-fold increase must be expected, which is demonstrated in actual trials properly matched to confounding factors. Discontinuation of clopidogrel for 5-7 days prior to urgent CABG as recommended by guidelines is not well adopted in clinical practice for several reasons.
Summary:
There is a moderately elevated risk of bleeding complications after CABG due to prior clopidogrel exposure alone. However, in clinical practice this risk is added often to patients who carry already elevated surgical risks (urgent procedures, worse coronary anatomy, history of previous myocardial infarction and prior percutaneous intervention), and after bleeding complications singular patients may suffer from consecutive adverse outcome. Cessation of clopidogrel in patients before CABG clearly prolongs hospitalization time and has an estimated 1% risk of coronary events during the waiting period. Risk and benefit have to be balanced in every individual case.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Angina IV: Management
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures